Trial · NCT00630253

Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia

NCT00630253, Phase 1, Phase 2, Completed, Masonic Cancer Center, University of Minnesota; results first posted 2021-10-12

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia. Trials, record NCT00630253. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00630253

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
NCT number: NCT00630253
Status: Completed
Phases: Phase 1, Phase 2
Enrollment: 31 participants, actual
Lead sponsor: Masonic Cancer Center, University of Minnesota
Conditions: Fanconi Anemia
Interventions: Anti-Thymocyte Globulin, Cyclophosphamide, Fludarabine, Hematopoietic Stem Cell Transplantation, Methylprednisolone, Filgrastim, Cyclosporine, Mycophenolate Mofetil
First posted: 2008-03-06
Last updated: 2021-10-12
Results first posted: 2021-10-12

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Experiencing Graft Failure	From Day 1 to event, assessed up to100 days	graft failure = absolute neutrophil count (ANC) \<5 x 10\^8/L and an acellular bone marrow aspirate/biopsy
Secondary	Number of Participants With Acute Graft-Versus-Host Disease (GVHD)	Day 42	Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.
Secondary	Number of Participants Experiencing Overall Survival	1 Year	The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate. Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive.
Secondary	Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)	1 Year	Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.
Secondary	Number of Participants With Transplant Related Deaths	Day 100	In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Participants Experiencing Graft Failure	From Day 1 to event, assessed up to100 days	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Acute Graft-Versus-Host Disease (GVHD)	Day 42	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants Experiencing Overall Survival	1 Year	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)	1 Year	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Transplant Related Deaths	Day 100	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group15

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Number of Participants Experiencing Graft Failure	Marrow Isolex	0	Participants
Number of Participants Experiencing Graft Failure	UCB Arm	0	Participants
Number of Participants Experiencing Graft Failure	Marrow Clinimax	0	Participants
Number of Participants With Acute Graft-Versus-Host Disease (GVHD)	Marrow Isolex	0	Participants
Number of Participants With Acute Graft-Versus-Host Disease (GVHD)	UCB Arm	0	Participants
Number of Participants With Acute Graft-Versus-Host Disease (GVHD)	Marrow Clinimax	0	Participants
Number of Participants Experiencing Overall Survival	Marrow Isolex	15	Participants
Number of Participants Experiencing Overall Survival	UCB Arm	8	Participants
Number of Participants Experiencing Overall Survival	Marrow Clinimax	5	Participants
Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)	Marrow Isolex	2	Participants

1 to 10 of 15Source ClinicalTrials.gov

See all 15 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Marrow Isolex	16
Overall Study	STARTED	Umbilical Cord Blood (UCB) Arm	9
Overall Study	STARTED	Marrow Clinimax	6
Overall Study	COMPLETED	Marrow Isolex	16
Overall Study	COMPLETED	Umbilical Cord Blood (UCB) Arm	9
Overall Study	COMPLETED	Marrow Clinimax	6
Overall Study	NOT COMPLETED	Marrow Isolex	0
Overall Study	NOT COMPLETED	Umbilical Cord Blood (UCB) Arm	0
Overall Study	NOT COMPLETED	Marrow Clinimax	0

Source ClinicalTrials.gov

Adverse events78

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Brain Infarction	Nervous system disorders	Marrow Isolex	1	16	1
other	Brain Infarction	Nervous system disorders	UCB Arm	0	9	0
other	Brain Infarction	Nervous system disorders	Marrow Clinimax	0	6	0
other	Cardiac arrect	Cardiac disorders	Marrow Isolex	0	16	0
other	Cardiac arrect	Cardiac disorders	UCB Arm	0	9	0
other	Cardiac arrect	Cardiac disorders	Marrow Clinimax	1	6	1
other	Cardiopumonary shock	Cardiac disorders	Marrow Isolex	0	16	0
other	Cardiopumonary shock	Cardiac disorders	UCB Arm	0	9	0
other	Cardiopumonary shock	Cardiac disorders	Marrow Clinimax	1	6	1
other	Cystitis	Infections and infestations	Marrow Isolex	2	16	2

1 to 10 of 78Source ClinicalTrials.gov

See all 78 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Marrow Isolex	1	16
Total, all-cause mortality	UCB Arm	1	9
Total, all-cause mortality	Marrow Clinimax	1	6
Total, other adverse events	Marrow Isolex	9	16
Total, other adverse events	UCB Arm	6	9
Total, other adverse events	Marrow Clinimax	5	6
Total, serious adverse events	Marrow Isolex	0	16
Total, serious adverse events	UCB Arm	0	9
Total, serious adverse events	Marrow Clinimax	1	6

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00630253

GET https://conductscience.org/api/trials/v1/NCT00630253/events?page=2

API reference For AI assistants